Drugmaker

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion

Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use of AI and data science to support development of new medicines

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter

The Mumbai-based company said its profit rose to Rs 137 crore (nearly $16 million) for the three months ended Dec. 31 from Rs 119 crore a year earlier

The deal is the latest in a string of acquisitions by J&J as it looks to drive growth beyond 2025

The Indian IPO market has been bustling this year, with over 300 companies having raised $17.5 billion as of mid-December, more than double the amount raised last year

But this inconspicuous pharmaceutical company is part of a lucrative trade in leading-edge technology to Russia that has the US and its European allies worried at India's burgeoning role

The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs

The European Commission handed down the 331 million euro ($354 million) fine in 2014 to Servier, as well as fines to generic drugmakers Teva, Unichem and its subsidiary Niche, Matrix

The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service

For Novo Holdings, which invests in life science companies and had assets of 108 billion euros ($115.86 billion) at end-2022, its recent investment in India was its largest in Asia to date

IndiaMART, one of India's top online marketplaces, allows dealers to sell on its website after a nominal background check and says it has minimal control over what is advertised and sold

He urged patients not to buy copycat versions of Wegovy, warning they could be unsafe

The DCGI has cautioned against the consumption of Abbott's antacid Digene gel citing safety concerns, even as the US-based drugmaker recalled several batches of the medicine manufactured at its Goa facility. According to a letter by the Drugs Controller General of India (DCGI), it was reported on August 9 that a bottle of Digene Gel (mint flavour), batch no 51030307, used by customers was of regular taste (sweet) and light pink in colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour as per a complaint. "Accordingly, M/s Abbott India Limited, Verna Industrial Estate, Salcette, Goa- vide letter dated August 11, 2023, informed DCGI office for voluntary recall of impugned product Digene Mint flavour batch no 51030307 and Digene Gel orange having batch no 50035107, 50035207, 50035307, 50035407 and voluntary stopped production of all variants of Digene Gel manufactured at their Goa facility," the DCGI letter stated. Further, Abbott India

The company's share price closed up 0.7 per cent to DKK 1,311 ($190), giving the company a market capitalisation of $428 billion

A Punjab-based drugmaker was asked to stop all manufacturing activities after samples collected from its premises, following an alert by the WHO, were found to be "not of standard quality", the Lok Sabha was informed on Friday. Minister of State for Health Bharati Pravin Pawar, in a written reply in the Lower House of Parliament, said the World Health Organization (WHO) issued a medical product alert for a batch of India-made Guaifenesin syrup in the Marshall Islands and the Federated States of Micronesia. Subsequent to the reports, the Central Drugs Standard Control Organisation (CDSCO) in coordination with State Drugs Authority, Punjab, conducted a joint investigation at M/s QP Pharmachem Ltd in Punjab. "Drug samples drawn from the manufacturing premises under the provisions of Drugs and Cosmetics Act, 1940 for test and analysis were declared as 'not of standard quality'," the minister said. "Further, the State Licensing Authority has directed the firm to stop all manufacturing .

India has suspended a drugmaker's manufacturing licence after the World Health Organization flagged contamination in its cough syrups found in the Mashall Islands and Micronesia in April

As part of its growth plans, Ajanta Pharma is looking to enhance its presence across select geographies with high growth potential in Asia and Africa. In its Annual Report for 2022-23, the Mumbai-based drug maker stated that it intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics. "As we achieve formidable positions in many markets, our strategy now entails enhancing focus on select countries from our geographical presence, which promises high growth potential," Ajanta Pharma informed its shareholders. These territories offer a large branded generics pharma market size, but the company's presence still remains small, it added. "We plan to ramp up our presence in these markets and add value to the patients' choices through our differentiated product portfolio," the drug firm said. The company's branded generics business accounted for 73 per cent of its revenues in FY 2023, with Indian, rest of Asia and Africa ...

Novo and Lilly's experimental obesity pills helped people lose about 15% of body weight, similar to weight-loss shots on the market already, according to findings presented

Nigeria's National Agency for Food and Drugs Administration and Control said that samples of the Indian-made paracetamol suspension, Para Clear, exported to Liberia contained toxin ethylene glycol